Prodrug Activation in Cancer Cells Using Molecular Switches

The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.

Patents:
US 20,110,135,620

Inventor(s): OSTERMEIER MARC ALAN [US]; WRIGHT CHAPMAN M [US]

Type of Offer: Licensing



« More Biotech Patents

---